NCT00947895 (RECLAIM) is a Phase 2/Phase 3 clinical trial of Methylprednisolone in Multiple Sclerosis, sponsored by Neurologique Foundation, Inc..

Who is sponsoring NCT00947895?

NCT00947895 is sponsored by Neurologique Foundation, Inc..

What drugs are being tested in NCT00947895?

Interventions in NCT00947895: Methylprednisolone, ACTH, IV placebo, IM placebo.

What condition does NCT00947895 study?

NCT00947895 studies Multiple Sclerosis.

Is NCT00947895 still recruiting?

NCT00947895 is currently terminated. Last updated 21 March 2016.

Last reviewed 2016-03-21 · How we verify

NCT00947895: RECLAIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study

Terminated Phase 2/Phase 3 Last updated 21 March 2016

What this trial tests

Phase 2/Phase 3 trial testing Methylprednisolone in Multiple Sclerosis in 30 participants. Terminated before completion.

Timeline

1 October 2009

Primary endpoint
1 January 2011

1 January 2011

Quick facts

Lead sponsor	Neurologique Foundation, Inc.
Phase	Phase 2/Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	1 October 2009
Primary completion	1 January 2011
Estimated completion	1 January 2011
Sites	1 location across United States

Drugs / interventions tested

Methylprednisolone (methylprednisolone) — full drug profile →
ACTH — full drug profile →
IV placebo
IM placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Neurologique Foundation, Inc.

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).
Time frame: 12 weeks

Sponsor's own description

The purpose of this study is to compare intramuscular (IM) ACTH (adrenocorticotropin hormone) and intravenous (IV) methylprednisolone (Solumedrol) for the treatment of an MS (Multiple Sclerosis) relapse (exacerbation) after sub-response to an initial 3 day course of IV methylprednisolone.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.
Wiendl H, Meuth SG. · · 2015 · cited 24× · PMID 26033077 · DOI 10.1007/s40265-015-0411-0

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Ped · Phase 2 · not yet recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
NCT07265258 — A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease · Phase 4 · not yet recruiting

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00947895 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurologique Foundation, Inc.
Last refreshed: 21 March 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00947895.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing